UNICREDIT BANK/CALL/ELI LILLY & CO/1300/0.1/17.06.26 | Real-time BOERSE MUENCHEN 12:40:15 04/06/2024 BST | ||
| 5.26 EUR | 0.00% |
|
| Current month | +3.95% | ||
| 1 month | +49.01% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
| Date | Price | Change |
|---|---|---|
| 04/06/24 | 5.26 | 0.00% |
| 03/06/24 | 5.26 | +3.95% |
| 31/05/24 | 5.06 | 0.00% |
| 30/05/24 | 5.06 | +2.02% |
| 29/05/24 | 4.96 | +1.02% |
Real-time BOERSE MUENCHEN
Last update June 04, 2024 at 12:40 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
UniCredit
|
| WKN | HD4LBU |
| ISIN | DE000HD4LBU2 |
| Date issued | 12/04/2024 |
| Strike | 1,300 $ |
| Maturity | 17/06/2026 (744 Days) |
| Parity | 10 : 1 |
| Emission price | 4.74 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 5.26 € |
|---|---|
| Lowest since issue | 3.41 € |
| Spread | 0.65 € |
| Spread % | 11.28% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
831.3
USD
Average target price
852.5
USD
Spread / Average Target
+2.56%
- Stock Market
- Warrants
- Warrant